Alimera Sciences, pSivida Limited Amend Medidur™ FA Collaboration Agreement
News Mar 18, 2008
Alimera Sciences and pSivida Ltd have announced that they have amended their license and collaboration agreement relating to Medidur™ FA, the companies’ Phase III investigative treatment for diabetic macular edema (DME), and other Medidur products.
Alimera is increasing its equity in the future profits of Medidur FA from 50 to 80 percent in exchange for consideration of up to approximately US$78m to pSivida.
Consideration to pSivida includes an up-front payment of US$12m, a US$25m milestone payment upon FDA approval of Medidur™ FA, other payments of up to approximately US$21m by September 30, 2012, and assumption of pSivida's research and development funding obligations estimated at approximately US$20m.
“We are very pleased with this agreement as it provides us with the opportunity to increase our stake and consolidate the development and commercialization of our late stage DME product Medidur FA,” said Dan Myers, President and CEO of Alimera Sciences.
“In addition, we will further advance the delivery system’s application in other serious ophthalmic conditions like dry age-related macular degeneration (AMD), using exploratory treatments such as the groundbreaking work we are doing around NADPH oxidase inhibitors.”
"We believe this is a great deal for pSivida and its shareholders as it gives the company a significant financial interest in very exciting products and economics that eliminate our need for equity financing for the foreseeable future under our current plans,” said pSivida Managing Director, Dr. Paul Ashton.
“This new agreement with Alimera Sciences is expected to significantly reduce our burn rate going forward as the Company’s two lead ophthalmology programs in development are now funded by our partners."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE